AU2014228386B2 - Methods of treatment of pediatric solid tumor - Google Patents

Methods of treatment of pediatric solid tumor Download PDF

Info

Publication number
AU2014228386B2
AU2014228386B2 AU2014228386A AU2014228386A AU2014228386B2 AU 2014228386 B2 AU2014228386 B2 AU 2014228386B2 AU 2014228386 A AU2014228386 A AU 2014228386A AU 2014228386 A AU2014228386 A AU 2014228386A AU 2014228386 B2 AU2014228386 B2 AU 2014228386B2
Authority
AU
Australia
Prior art keywords
individual
taxane
composition
years old
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014228386A
Other languages
English (en)
Other versions
AU2014228386A1 (en
Inventor
Bouchra BENETTAIB
Neil P. Desai
Ileana ELIAS
Markus Renschler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abraxis Bioscience LLC
Original Assignee
Abraxis Bioscience LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abraxis Bioscience LLC filed Critical Abraxis Bioscience LLC
Publication of AU2014228386A1 publication Critical patent/AU2014228386A1/en
Application granted granted Critical
Publication of AU2014228386B2 publication Critical patent/AU2014228386B2/en
Priority to AU2019201357A priority Critical patent/AU2019201357A1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5052—Proteins, e.g. albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
AU2014228386A 2013-03-13 2014-03-10 Methods of treatment of pediatric solid tumor Ceased AU2014228386B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2019201357A AU2019201357A1 (en) 2013-03-13 2019-02-27 Methods of treatment of pediatric solid tumor

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361780658P 2013-03-13 2013-03-13
US61/780,658 2013-03-13
US201361805817P 2013-03-27 2013-03-27
US61/805,817 2013-03-27
US201361829940P 2013-05-31 2013-05-31
US61/829,940 2013-05-31
US201361909868P 2013-11-27 2013-11-27
US61/909,868 2013-11-27
PCT/US2014/022541 WO2014143613A1 (en) 2013-03-13 2014-03-10 Methods of treatment of pediatric solid tumor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2019201357A Division AU2019201357A1 (en) 2013-03-13 2019-02-27 Methods of treatment of pediatric solid tumor

Publications (2)

Publication Number Publication Date
AU2014228386A1 AU2014228386A1 (en) 2015-09-24
AU2014228386B2 true AU2014228386B2 (en) 2018-11-29

Family

ID=51537501

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2014228386A Ceased AU2014228386B2 (en) 2013-03-13 2014-03-10 Methods of treatment of pediatric solid tumor
AU2019201357A Abandoned AU2019201357A1 (en) 2013-03-13 2019-02-27 Methods of treatment of pediatric solid tumor

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2019201357A Abandoned AU2019201357A1 (en) 2013-03-13 2019-02-27 Methods of treatment of pediatric solid tumor

Country Status (12)

Country Link
US (1) US20160015817A1 (enExample)
EP (1) EP2968253A4 (enExample)
JP (3) JP6387389B2 (enExample)
KR (1) KR20150126671A (enExample)
CN (1) CN105209035A (enExample)
AU (2) AU2014228386B2 (enExample)
CA (1) CA2903470A1 (enExample)
HK (1) HK1219231A1 (enExample)
IL (1) IL240987A0 (enExample)
MX (1) MX2015011783A (enExample)
NZ (1) NZ630367A (enExample)
WO (1) WO2014143613A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
US9675578B2 (en) 2006-12-14 2017-06-13 Abraxis Bioscience, Llc Breast cancer therapy based on hormone receptor status with nanoparticles comprising taxane
HRP20192259T1 (hr) 2009-04-15 2020-03-06 Abraxis Bioscience, Llc Pripravci nanočestica bez priona i metode njihove proizvodnje
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
US9393318B2 (en) 2010-03-29 2016-07-19 Abraxis Bioscience, Llc Methods of treating cancer
KR20130088116A (ko) 2010-06-04 2013-08-07 아브락시스 바이오사이언스, 엘엘씨 췌장암의 치료 방법
AU2012249371B2 (en) 2011-04-28 2017-06-08 Abraxis Bioscience, Llc Intravascular delivery of nanoparticle compositions and uses thereof
PL2790675T3 (pl) 2011-12-14 2019-12-31 Abraxis Bioscience, Llc Zastosowanie polimerowych rozczynników do liofilizacji lub zamrażania cząstek
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
JP6349381B2 (ja) 2013-03-12 2018-06-27 アブラクシス バイオサイエンス， エルエルシー 肺がんを処置する方法
JP6309610B2 (ja) 2013-03-14 2018-04-11 アブラクシス バイオサイエンス， エルエルシー 膀胱がんを処置する方法
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
SMT202100642T1 (it) 2015-06-29 2022-03-21 Abraxis Bioscience Llc Nanoparticelle comprendenti sirolimus e un'albumina per l'uso nel trattamento di tumori a cellule epitelioidi
AU2019239953B2 (en) 2018-03-20 2025-01-02 Abraxis Bioscience, Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
IL292439B2 (en) 2019-10-28 2026-05-01 Abraxis Bioscience Llc Pharmaceutical preparations of albumin and rapamycin

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1155692B1 (en) * 2000-05-18 2004-05-26 ACS DOBFAR S.p.A. Use of Paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby
WO2011063309A1 (en) * 2009-11-20 2011-05-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
WO2011123393A1 (en) * 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
WO2011153009A1 (en) * 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US6749868B1 (en) 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
CN1101700C (zh) * 1997-12-05 2003-02-19 上海众联生化技术开发有限公司 多肽口服液
DK1585548T3 (en) 2002-12-09 2018-09-03 Abraxis Bioscience Llc COMPOSITIONS AND PROCEDURES FOR THE DELIVERY OF PHARMACOLOGICAL AGENTS
CN1261161C (zh) * 2003-11-10 2006-06-28 钱汶光 复方干扰素诱生剂口含片
CN103169729A (zh) 2005-02-18 2013-06-26 阿布拉科斯生物科学有限公司 治疗剂的组合和给予方式以及联合治疗
CN101291658B (zh) 2005-08-31 2014-04-16 阿布拉科斯生物科学有限公司 用于制备稳定性增加的水难溶性药物的组合物和方法
WO2008137148A2 (en) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Methods and compositions for treating pulmonary hypertension

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1155692B1 (en) * 2000-05-18 2004-05-26 ACS DOBFAR S.p.A. Use of Paclitaxel stabilized with albumin for preparing a drug for the treatment of solid tumors and the drug obtained thereby
WO2011063309A1 (en) * 2009-11-20 2011-05-26 Infinity Pharmaceuticals, Inc. Methods and compositions for treating hedgehog-associated cancers
WO2011123393A1 (en) * 2010-03-29 2011-10-06 Abraxis Bioscience, Llc Methods of enhancing drug delivery and effectiveness of therapeutic agents
WO2011153009A1 (en) * 2010-06-02 2011-12-08 Abraxis Bioscience, Llc Methods of treating bladder cancer

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DESAI N ET AL, "Enhanced antitumor activity and safety of albumin-bound nab-docetaxel versus polysorbate 80-based docetaxel", EUROPEAN JOURNAL OF CANCER. SUPPLEMENT; 07 -10, 2006, vol. 4, page 49 *
DOZ ET AL., "Phase I trial and pharmacological study of a 3-hour paclitaxel infusion in children with refractory solid tumours: a SFOP study", BR. J CANCER, (2001), vol. 84, no. 5, pages 604 - 610 *
HAWKINS M J ET AL, "Protein nanoparticles as drug carriers in clinical medicine", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 60, no. 8, doi:10.1016/J.ADDR.2007. pages 876 - 885, ( *
IZBICKA ELZBIETA ET AL, "Molecular determinants of differential sensitivity to docetaxel and paclitaxel in human pediatric cancer models", ANTICANCER RESEARCH - , (2006-05-01), vol. 26, no. 3A 1983 - 1988 *
JAME ABRAHAM, "nab-Paclitaxel for treatment of solid tumors: beyond breast cancer.", COMMUN ONCOL., (2008), vol. 5, no. S7, pages 8 - 15 *
SOUTHWELL T KAY ET AL, "Antitumor activity of Taxotere and paclitaxel against three human pediatric tumor xenograft models", AMERICAN ASSOCIATION FOR CANCER RESEARCH. PROCEEDINGS OF THE ANNUAL MEETING; [CANCER RESEARCH; APRIL 2004, *
STINCHOMBE ET AL., "Phase 1 Trial of Nanoparticle Albumin-Bound Paclitaxel in combination with Gemcitabine in patients with Thoracic malignancies", J THORAC ONCOL., (2008), vol. 3, no. 5, pages 521 - 526 *
UCHEGBU ET AL., "Nanomedicines and Nanodiagnostics Come of Age", J. PHARM. SCI., (2013), vol. 102, no. 2, pages 305 - 310 *
YAMADA ET AL.,, "Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors", JPN J CLIN ONCOL;, (2010), vol. 40, no. 5, pages 404 - 411 *

Also Published As

Publication number Publication date
MX2015011783A (es) 2015-12-01
JP2019163334A (ja) 2019-09-26
AU2019201357A1 (en) 2019-03-21
EP2968253A1 (en) 2016-01-20
JP2016512513A (ja) 2016-04-28
IL240987A0 (en) 2015-11-30
EP2968253A4 (en) 2016-11-02
CA2903470A1 (en) 2014-09-18
NZ630367A (en) 2017-02-24
US20160015817A1 (en) 2016-01-21
HK1219231A1 (zh) 2017-03-31
AU2014228386A1 (en) 2015-09-24
JP2018062528A (ja) 2018-04-19
KR20150126671A (ko) 2015-11-12
CN105209035A (zh) 2015-12-30
JP6387389B2 (ja) 2018-09-05
WO2014143613A1 (en) 2014-09-18

Similar Documents

Publication Publication Date Title
AU2019201357A1 (en) Methods of treatment of pediatric solid tumor
AU2018200347B2 (en) Methods of treatment of pancreatic cancer
US8927019B2 (en) Methods and compositions for treating recurrent cancer
EP2405750B1 (en) Combination therapy with thiocolchicine derivatives
TWI495467B (zh) 肝細胞癌之治療方法
AU2011261684B2 (en) Methods of treating bladder cancer
CA3039582A1 (en) Methods of treating biliary tract cancer
HK1165957A (en) Combination therapy with thiocolchicine derivatives
HK1165957B (en) Combination therapy with thiocolchicine derivatives

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired